News Coronavirus What are antibody therapies and who is developing them for COVID-19?

What are antibody therapies and who is developing them for COVID-19?

While some potential vaccines have emerged in the global race to find a way to stop the spread of COVID-19, many scientists and researchers believe antibody based therapies hold great promise for treating people already infected with the disease.

HOW DO ANTIBODY THERAPIES WORK?

These therapies use antibodies generated by infected humans or animals to fight off the disease in patients. They date back to the late 19th century, when researchers used a serum derived from the blood of infected animals to treat diphtheria.

For COVID-19 treatment, researchers are studying the use of convalescent plasma and other treatments made with blood from recently recovered patients.

More recently, scientists have developed treatments called monoclonal antibodies — antibodies that can be isolated and manufactured in large quantities to treat diseases like Ebola or cancer. Companies, like Eli Lilly and Co and Regeneron Pharmaceuticals in the United States, are trying to use this approach to develop their treatments.

Unlike convalescent plasma, manufacturers do not need a steady supply of antibody-rich blood to produce monoclonal antibodies, so this approach could be easier to scale up.

HOW ARE THEY DIFFERENT FROM VACCINES?

In general, the goal of a vaccine is to generate an immune response that can prevent someone from getting ill with a disease, whereas antibody-derived products are generally designed to treat disease.

And while some drugmakers have suggested antibody treatments can be used prophylactically – Regeneron’s Chief Scientific Officer George Yancopoulos has said their treatment could be a bridge to a vaccine – it could be expensive.

“You might go into nursing homes or the military and use it because antibodies have a pretty long half life,” said Dr. Betty Diamond, Director of Molecular Medicine at the Feinstein Institutes for Medical Research.

“You might decide that you are going to use this as a prevention in this very high risk group, but you wouldn’t do that for the whole country.”

The amount of protein in antibody drugs makes the treatment more expensive than vaccines in general, Feng Hui, chief operating officer at Shanghai Junshi Biosciences, said.

Antibody drugs contain hundreds, or even over a thousand times more protein than found in a vaccine shot.

WHO IS DEVELOPING ANTIBODY THERAPIES FOR COVID-19?

Eli Lilly is collaborating with Junshi and Canadian biotech firm AbCellera Biologics to develop different antibody treatments, both of which have started early stage testing in humans.

Regeneron plans to start clinical studies later this month to test its antibody cocktail treatment, which was derived from antibodies from genetically-modified mice. It aims to have hundreds of thousands of preventative doses available “by the end of the summer or the fall.”

The CoVIg-19 Plasma Alliance, which includes Japan’s Takeda Pharmaceuticals and CSL Behring, is working on hyperimmune globulin therapy derived from convalescent plasma, which could offer a standardized dose of antibodies and doesn’t need to be limited to patients with matching blood types.

The Antibody Therapy Against Coronavirus (ATAC) project, funded by the European Commission and led by Sweden’s Karolinska research institute, is looking at a similar approach as well as monoclonal antibodies. Under the project, monoclonal antibodies extracted from convalescent plasma are now being tested on human volunteers in Germany and on animals in Switzerland.

Britain’s GlaxoSmithKline is working with Vir Biotechnology Inc to develop potential antibody treatments which select the best antibodies out of the plasma.

AbbVie has also announced a collaboration to develop antibody therapies.

Singapore’s state research body A*Star is working with Japan’s Chugai Pharmabody Research on an antibody for clinical use.

(Reuters)

Top Stories

PM Mitsotakis: Greece-Egypt’s agreement on maritime zones a national success

Prime Minister Kyriakos Mitsotakis said on Friday that the agreement between Greece and Egypt for the delimitation of their maritime zones, reached on Thursday,...

Cyprus’ President calls on Cypriots to donate food for Lebanon

Cyprus' President Nicos Anastasiades has called on Cypriot citizens, companies and businesses to contribute by donating generously to the campaign for collecting specific kinds...

Cyprus rescue teams begin operations in Beirut

Cyprus rescue teams which are in Lebanon began their operations since 7 am on Friday, in cooperation with a team from Qatar in Beirut`s...

Toddler almost drowned in Paralimni

A 14-month-old girl almost drowned on Friday morning at Paralimni. According to police, it was around 8:30 am when the baby girl who resides in...

Municipalities in partial suspension of payments

The chairman of the Union of Municipalities Andreas Vyras, revealed the dire financial situation in which the municipalities find themselves due to reduced revenues...

Taste

Octopus ‘Kathisto’ (or Octopus braised in Wine)

Ingredients: 1/2 cup Greek extra virgin olive oil 2 medium onions, chopped fine 1 large octopus, about 2kg (cleaned and kept whole) 3/4 cup dry red wine 1/3 cup...

Homemade lemonade

Ingredients: 1 cup lemon juice 1 cup sugar Method: Thoroughly wash the lemons with soap and warm water. Roll each lemon with the palm of your hand, pressing...

‘Striftaria’ mini cheese pies

Ingredients 1 ½ cup milk 2 tbsps. flour 4 tsps. of butter 3 eggs, slightly beaten + 1 extra with 1 tbs. of milk for spreading 1 pack of...

Mini potato canapes baked on salt

Ingredients Serves: 12 1kg small Cypriot potatoes rock salt, as needed 250g salted butter 300ml full fat cremé frâiche 1 pot cod or salmon roe Method Prep:20min › Cook:35min › Ready in:55min Take...